Search

everythinglearnresearchcommunity

for

Search:↓

A user is comparing Capillus Ultra and Capillus ONE for hair loss treatment, questioning if the number of diodes matters. Another user suggests the OMG helmet as the only worthwhile option.

A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

A user shared their positive experience with the Omnilux Red Light mask for skin and potential hair benefits, while also using Minoxidil, Dutasteride, and RU58841. They recommend the mask for those interested in skincare and red light therapy, despite being unsure of its effectiveness for hair growth.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.

Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

User Topher1999 achieved hair regrowth using Dutasteride 3 times a week and microneedling with Dr. Pen Ultima A6 every 2 weeks for 9 months. They believe microneedling is the main reason for hairline gains.

Dermal incision with verteporfin is being explored as a potential hair loss treatment by dermatologist Melissa Toyos, with promising before-and-after photos shared on social media. The conversation discusses its potential effectiveness compared to other treatments like Minoxidil, Finasteride, and RU58841.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.